| Company Name: | ResMed, Inc. | | Ticker Symbol: | RMD | | | WWW Address: | www.resmed.com.au | | CEO: | Kieran T. Gallahue | | No. of Employees: | 2,900 | | Common Issue Type: | CS | | Business Description: | The Company through its subsidiaries designs, manufactures and markets equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea.
|
| | | Industry Information: | HEALTH SERVICES - Medical Appliances & Equipment [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 50.47 |  0.22 | 44.79 | 51.15 | 50.5 | 51.00 | 50.19 | 312642 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 3,785.3 | 75.0 | 0.57 | 1.90 | 0.00 | 24.1 | 0.0 | 51.64 - 31.49 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 50.47 | $ | | PE Ratio - LTM | 24.1 | |
| Market Capitalisation | 3,783.5 | mil |
| Latest Shares Outstanding | 75.0 | mil |
| Earnings pS (EPS) | 1.90 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 317,495 | $ |
| Effective Tax Rate | 27.4 | % |
| Float | 73.8 | mil |
| Float as % of Shares Outstanding | 98.0 | % |
| Foreign Sales | 427 | mil |
| Domestic Sales | 493 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 31.10 | % |
| Research & Devlopment (R&D) as % of Revenue | 6.70 | % |
| Gross Profit Margin | 65.7 | % |
| EBITDA Margin | 27.9 | % |
| Pre-Tax Profit Margin | 23.3 | % |
| Assets Turnover | 0.7 | % |
| Return on Assets (ROA) | 9.9 | % |
| Return on Equity (ROE) | 13.3 | % |
| Return on Capital Invested (ROCI) | 12.4 | % |
| Current Ratio | 3.2 | |
| Leverage Ratio (Assets/Equity) | 1.3 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.14 | |
| LT Debt/Total Capital | 7.0 | % |
| Working Capital pS | 8.64 | $ |
| Cash pS | 6.37 | $ |
| Book-Value pS | 16.05 | $ |
| Tangible Book-Value pS | 12.62 | $ |
| Cash Flow pS | 2.86 | $ |
| Free Cash Flow pS | 1.84 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 3.14 | |
| Price/Tangible Book Ratio | 4.00 | |
| Price/Cash Flow | 17.6 | |
| Price/Free Cash Flow | 27.5 | |
| P/E as % of Industry Group | 84.0 | % |
| P/E as % of Sector Segment | 11.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.4 | 99 | 6,251 | 3,123 |
| 4 Weeks | 51.64 | 46.84 | 49.21 | 2.6 | 96 | 8,089 | 129,430 |
| 13 Weeks | 51.64 | 42.87 | 45.79 | 10.2 | 103 | 6,995 | 419,729 |
| 26 Weeks | 51.64 | 36.30 | 37.07 | 36.1 | 113 | 6,261 | 776,390 |
| 52 Weeks | 51.64 | 31.49 | 36.34 | 38.9 | 113 | 7,324 | 1,816,461 |
| YTD | 51.64 | 31.49 | - | 34.7 | 110 | 7,443 | 1,682,070 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 50.63 | 50.18 | 47.79 | 43.36 | 41.49 | 0.57 | 0.58 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 20.51 | 94.5 | 12.00 |
| Income | 16.53 | 72.4 | 21.72 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 7.62 | NA | 0.51 |
| R&D | 20.08 | NA | 16.13 |
| Normalized Inc. | 14.52 | NA | 22.22 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 13.3 | 13.3 | 10.2 |
| Earnings % | 50.2 | 50.2 | 32.8 |
| EPS % | 52.8 | 52.8 | 35.7 |
| EPS $ | 0.19 | 0.19 | 0.50 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 38.74 |
| Current Ratio | 3.2 |
| Quick Ratio (Acid Test) | 2.3 |
| Liquidity Ratio (Cash) | 1.54 |
| Receivables Turnover | 4.3 |
| Average Collection Period | 84 |
| Working Capital/Equity | 52.4 |
| Working Capital pS | 7.76 |
| Cash-Flow pS | 2.66 |
| Free Cash-Flow pS | 1.62 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 7.42 |
| Financial Leverage Ratio (Assets/Equity) | 1.4 |
| Debt Ratio | 26.0 |
| Total Debt/Equity (Gearing Ratio) | 0.15 |
| LT Debt/Equity | 0.08 |
| LT Debt/Capital Invested | 10.2 |
| LT Debt/Total Liabilities | 24.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 2.23 |
| Tobin's Q Ratio | 2.51 |
| Current P/E Ratio - LTM | 24.10 |
| Enterprise Value (EV)/EBITDA | 15.18 |
| Enterprise Value (EV)/Free Cash Flow | 35.08 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 4.00 |
| Price/Book Ratio - LTM | 3.14 |
| Price/Cash Flow Ratio | 17.6 |
| Price/Free Cash Flow Ratio - LTM | 27.5 |
| Price/Sales Ratio | 3.98 |
| P/E Ratio (1 month ago) - LTM | 23.8 |
| P/E Ratio (26 weeks ago) - LTM | 21.9 |
| P/E Ratio (52 weeks ago) - LTM | 24.9 |
| 5-Y High P/E Ratio | 66.1 |
| 5-Y Low P/E Ratio | 14.7 |
| 5-Y Average P/E Ratio | 34.4 |
| Current P/E Ratio as % of 5-Y Average P/E | 70 |
| P/E as % of Industry Group | 84.0 |
| P/E as % of Sector Segment | 11.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 23.6 |
| PER SHARE FIGURES |
| LT Debt pS | 1.25 |
| Current Liabilities pS | 3.58 |
| Tangible Book Value pS - LTM | 12.62 |
| Book Value pS - LTM | 16.05 |
| Capital Invested pS | 16.13 |
| Cash pS - LTM | 6.37 |
| Cash Flow pS - LTM | 2.86 |
| Free Cash Flow pS - LTM | 1.84 |
| Earnings pS (EPS) | 1.90 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 13.28 |
| Free Cash Flow Margin 5YEAR AVG | 2.89 |
| Net Profit Margin | 15.9 |
| Net Profit Margin - 5YEAR AVRG. | 13.6 |
| Equity Productivity | 0.83 |
| Return on Equity (ROE) | 13.1 |
| Return on Equity (ROE) - 5YEAR AVRG. | 11.0 |
| Capital Invested Productivity | 0.76 |
| Return on Capital Invested (ROCI) | 12.1 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 9.9 |
| Assets Productivity | 0.60 |
| Return on Assets (ROA) | 9.7 |
| Return on Assets (ROA) - 5YEAR AVRG. | 8.0 |
| Gross Profit Margin | 65.7 |
| Gross Profit Margin - 5YEAR AVRG. | 65.3 |
| EBITDA Margin - LTM | 27.9 |
| EBIT Margin - LTM | 23.3 |
| Pre-Tax Profit Margin | 21.9 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 19.6 |
| Effective Tax Rate | 27.4 |
| Effective Tax Rate - 5YEAR AVRG. | 31.3 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 262 |
| Revenue per Employee | 317,495 |
| Net Income per Employee | 50,499 |
| Average Collection Period | 84 |
| Receivables Turnover | 4.3 |
| Day's Inventory Turnover Ratio | 178 |
| Inventory Turnover | 2.0 |
| Inventory/Sales | 17.1 |
| Accounts Payble/Sales | 5.25 |
| Assets/Revenue | 1.67 |
| Net Working Capital Turnover | 1.58 |
| Fixed Assets Turnover | 1.41 |
| Total Assets Turnover | 0.6 |
| Revenue per $ Cash | 2.22 |
| Revenue per $ Plant | 2.44 |
| Revenue per $ Common Equity | 0.83 |
| Revenue per $ Capital Invested | 0.76 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 31.5 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 32.6 |
| Research & Devlopment (R&D) as % of Revenue | 6.8 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 6.8 |
|
|  
|
| |
 |  |